Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry Lung Non-Small Cell Carcinoma NSCC Panel Test

An essential diagnostic test using immunohistochemistry to identify specific biomarkers in non-small cell lung carcinoma (NSCLC) tumor tissue, aiding in accurate diagnosis and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue sample. This can be submitted as a 10% Formal-saline or Formalin-fixed paraffin-embedded (FFPE) block.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required for this test. Ensure the submitted tissue sample is properly labeled and accompanied by a copy of the histopathology report, biopsy site information, and relevant clinical history.
Test priceKSh 37,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry Lung Non-Small Cell Carcinoma NSCC Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of non-small cell lung carcinoma (NSCLC).
  • ✓Classification of NSCLC subtypes.
  • ✓Guiding treatment decisions for lung cancer.
  • ✓Identifying potential targets for therapy.
  • ✓Patients with symptoms suggestive of lung cancer.
  • ✓Patients with a history of smoking or relevant exposures.
02

In plain language

What this test helps you understand

This test helps identify specific biomarkers in non-small cell lung carcinoma (NSCLC) tumor tissue. The results aid oncologists and pathologists in confirming the diagnosis, classifying the tumor subtype, and guiding treatment decisions, including the potential use of targeted therapies.
The Immunohistochemistry Lung Non-Small Cell Carcinoma (NSCLC) Panel Test is a vital diagnostic tool for evaluating lung cancer. This test uses advanced immunohistochemistry techniques to detect specific proteins (biomarkers) within tumor tissue samples. These biomarkers help oncologists and pathologists understand the characteristics of the NSCLC, which is crucial for determining the most effective treatment strategies.

This test measures the expression levels of key proteins, including ROS1, P40, TTF1, PDL1, and ALK D5F3. The presence and levels of these biomarkers provide important information about the tumor's type and potential response to specific therapies.

This test is typically recommended for patients diagnosed with lung cancer, especially NSCLC, or those presenting with symptoms suggestive of lung cancer, such as a persistent cough, chest pain, or unexplained weight loss. It is also relevant for individuals with a history of smoking or exposure to cancer-causing substances.

Understanding the results of this test allows for more precise diagnosis, guides the selection of targeted therapies, and contributes to better treatment planning and patient outcomes. Your doctor will interpret the results in the context of your overall health and clinical history.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required for this test. Ensure the submitted tissue sample is properly labeled and accompanied by a copy of the histopathology report, biopsy site information, and relevant clinical history.
SampleTumor tissue sample. This can be submitted as a 10% Formal-saline or Formalin-fixed paraffin-embedded (FFPE) block.
MethodologyImmunohistochemistry (IHC) using automated staining platforms.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Test results must be interpreted by a qualified healthcare professional in conjunction with clinical findings and other diagnostic tests. The presence or absence of biomarkers may not always predict treatment response definitively. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Immunohistochemistry (IHC) is a laboratory technique that uses antibodies to detect specific proteins (antigens) in tissue samples. In this test, it helps identify biomarkers associated with lung cancer.
This test helps determine the specific type of non-small cell lung cancer and identifies biomarkers that can guide treatment decisions, including targeted therapies.
A tissue sample from the tumor is required. This can be a formalin-fixed paraffin-embedded (FFPE) block or a 10% formalin-fixed tissue sample.
Turnaround time varies. Please contact the laboratory for specific details regarding this test.
A pathologist analyzes the tissue sample and generates the IHC report. Your oncologist will interpret these results in the context of your clinical situation.
This test helps characterize the type of lung cancer already diagnosed. It is typically performed after a cancer diagnosis has been made based on other tests like biopsy.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp